EUCTR2020-004835-26-IT进行中（未招募）1 期
Single-center, randomized, controlled study to evaluate the effects of a six-month treatment with renal glucose transport inhibitor (SGLT2i) drugs on markers of senescence, inflammation and tubulointerstitial damage in the kidney of patients with chronic kidney disease with or without type 2 diabetes - GLUTREPRO
IRCCS-A.O.U. SAN MARTINO-IST0 个研究点目标入组 38 人开始时间: 2021年8月2日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 38
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Adult (age 18-75 years)
- •- Albuminuria defined as urinary albumin ratio: creatinine = 25 mg / g (or protein ratio: creatinine = 30 mg / g) or albuminuria> 30 mg / 24h
- •- eGFR> 25 and <75 ml / minute 1.73 m2
- •- BMI between 19 kg / m2 and 30 kg / m2
- •- Treatment with an ACE inhibitor and / or ARB at the maximum tolerated dose (for the individual subject). The maximum tolerated dose for an individual subject may be less than the maximum labeled dose or may be zero if the medical reason is documented.
- •- Mean systolic and diastolic blood pressure (determined as the average of three repeated measurements) should be <180/90 mmHg
- •- Willingness to participate in the study (signing of informed consent)
- •Specific inclusion criteria
- •CKD AND T2DM
- •- Clinical diagnosis of T2DM for at least 1 year
- •- Value of hemoglobin A1c (HbA1c) <9.5%
- •-Patients treated only with metformin and/or repaglinide
- •- Diagnosis of diabetic nephropathy after renal biopsy made not more than 6 months before the screening visit (only for the subgroup of patients candidates for the second renal biopsy)
- •- Proteinuria> 1g / 24h (only for the subgroup of patients candidates for the second renal biopsy)
- •- Hemoglobin A1c (HbA1c) value> 6.5% (only for patients candidates for the second renal biopsy)
- •CKD WITHOUT T2DM
- •diagnosed with hypertension for at least 5 years
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 19
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 19
排除标准
- •Type 1 Diabetes
- •Hemoglobin A1c (HbA1c) value of > 9.5% during the Screening period (based on central laboratory measurement).
- •need for an adjunctive drugs on top on metformin and repaglinide
- •Hemoglobin A1c (HbA1c) value of < 6.5% only for patients candidated to the second kidney biopsy
- •Estimated glomerular filtration rate < 25 or > 75 ml/min/1.73m2 (according to the CKD-EPI) at screening
- •Untreated urinary or genital infection at screening and follow-up
- •Clear signs of volume depletion
- •Symptomatic hypotension, or systolic blood pressure < 90 or non-controlled hypertension
- •History of alcohol or drug abuse, anuria, dialysis, or acute kidney injury/acute renal failure in the 3 months prior to Screening Period
- •Heart, liver or kidney transplant
- •Acute coronary syndrome, stroke, or transient ischemic attack within 3 months prior to informed consent
- •Liver disease, defined by serum levels of alanine aminotransferase, aspartate aminotransferase, or alkaline phosphatase above 3 x upper limit of normal (ULN) during screening
- •Planned cardiac surgery or angioplasty within 3 months
- •Cancer or medical history of cancer (except for basal cell carcinoma) within the last 5 years
- •Treatment with anti-obesity drugs 3 months prior to informed consent or any other treatment at time of screening leading to unstable body weight (e.g. surgery, aggressive diet regimen, etc.)
- •SGLT2i treatment in the 10 weeks before the Screening Period
- •Treatment with systemic steroids at time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent
- •Any uncontrolled endocrine disorder except T2DM
- •Women who are pregnant or breastfeeding
- •Pre-menopausal women of child bearing potential who are not willing to employ effective contraception according to 2007 CTFG Recommendations related to contraception and pregnancy testing in clinical trials from screening for all the duration of the study
- •Patients with a known hypersensitivity to Dapagliflozin or other SGLT2- inhibitors, including hypersensitivity to excipients (e.g. lactose)
- •History of pancreatitis, or pancreatic surgery, diabetic ketoacidosis
- •Prior lower extremity amputation or current threat of amputation (eg, lower extremity ulcer and peripheral artery disease)
- •History of severe hypoglycaemia and hypoglycaemia unawareness.
- •Contraindication to MRI
研究者
相似试验
已完成
不适用
Study to evaluate the safety and effectiveness of the electro muscular stimulation device to improve skin elasticity, firmness and to reduce the signs of facial aging in healthy adultsCTRI/2012/01/002325Vercel Inc70
已完成
不适用
A randomised, single centre, controlled study to assess whether listening to self selected recorded music reduces the anxiety of patients undergoing their first radiotherapy treatment.anyone diagnosed with cancer needing radiotherapy - radical intent for treatmentanxiety during initial radiotherapyCancer - Other cancer typesACTRN12609000589280Peter MacCallum Cancer Centre100
进行中（未招募）
不适用
A single center, randomized, controlled study to determine the irritant potential of topical acne formulations on intact healthy skin on the back following repeated application during a 21-day treatment period - Cumulative irritiation testEUCTR2009-014550-14-DEDow Pharmaceutical Sciences, Inc on behalf of Coria Laboratories33
进行中（未招募）
不适用
clinical trial to evaluate the effectiveness of two administration schedules of CitraFleet to cleanse the coloEUCTR2013-001620-20-DEaboratorios Casen-Fleet S.L.U.320
进行中（未招募）
1 期
Combined treatement with human albumin and intravenous immunoglobulin in Alzheimer diseaseEUCTR2011-001598-25-ESINSTITUTO GRIFOLS, S.A.350